Red Canyon Resources Ltd. announced a non-brokered flow-through private placement to raise up to $1 million by issuing 5 million flow-through units at $0.20 each. The funds will support exploration on its Kendal and Osiris copper projects in British Columbia, with expenditures qualifying for Canadian tax credits. The offering includes warrants exercisable at $0.30 for 18 months and requires approval from the Canadian Securities Exchange. This financing aims to advance Red Canyon's exploration efforts, including ongoing geophysical surveys and planned drilling at high-priority targets.
Red Canyon's financing announcement is presented here with Pluang's Basic Materials sector data as of Oct 02, 2026 02:41 WIB. For readers following Basic Materials, 9 of 38 priced US stocks rose while 28 fell. Notable movers include FMC Corp at USD 8.64 with a -3.14% change and 100% buy order activity, MP Materials at USD 45.93 down -2.88% with 93% buy orders, and Lithium Americas Corp at USD 2.56 down -2.47% with 65% sell orders.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
